Preparation method and application of epimedin C solution for inhalation
By preparing a nebulized inhalation formulation containing ascorbic acid C, guaiacol, osmotic pressure regulator, and pH regulator, the problems of low bioavailability and insufficient lung targeting of ascorbic acid C were solved, achieving the effect of highly effective treatment of acute pneumonia and enhanced lung targeting.
Patent Information
- Application Number
- CN202512021980.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-30
- Publication Date
- 2026-02-17
AI Technical Summary
In the existing technology, ascorbic acid C has low bioavailability and insufficient lung targeting. Traditional oral administration has the first-pass effect and insufficient lung targeting, which limits its clinical application value. In addition, the content of ascorbic acid C in the existing nebulized inhalation formulation is low and unstable.
A nebulized inhalation formulation containing guaiacol, osmolarity regulator, and pH regulator was prepared for intratracheal administration. The composition and process were optimized to improve bioavailability and lung targeting, and antioxidants were added to enhance stability.
It significantly improved the bioavailability of Ascorbic acid C, enhanced lung targeting, reduced systemic toxicity, prolonged the duration of action of the drug in the lungs, and improved anti-inflammatory effects, while ensuring the stability of the formulation under high temperature and light conditions.